Using Neuromodulators for Salivary, Eccrine, and Apocrine Gland Disorders.
Journal
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
ISSN: 1524-4725
Titre abrégé: Dermatol Surg
Pays: United States
ID NLM: 9504371
Informations de publication
Date de publication:
01 Sep 2024
01 Sep 2024
Historique:
medline:
29
8
2024
pubmed:
29
8
2024
entrez:
28
8
2024
Statut:
ppublish
Résumé
Sialorrhea, hyperhidrosis, bromhidrosis, and chromhidrosis are common glandular disorders that substantially impact patients' health and quality of life. Botulinum toxin can safely and temporarily decrease gland secretions by targeting the parasympathetic cholinergic neurons, resulting in diminished saliva and sweat production. The objective of this article is to describe the applications of neuromodulators for the treatment of salivary, eccrine, and apocrine glands. PubMed was searched from inception to February 1, 2024 using search terms "neurotoxin," "botulinum toxin," "sialorrhea," "hyperhidrosis," "bromhidrosis," and "chromhidrosis." Incobotulinumtoxin A and Rimabotulinumtoxin B are approved by the FDA for the treatment of sialorrhea. Onabotulinumtoxin A is the only FDA-approved botulinum toxin for axillary hyperhidrosis and is used off-label for hyperhidrosis of nonaxillary sites, bromhidrosis, and chromhidrosis. Compared to botulinum toxin serotype A, serotype B has been associated with more immunogenicity, which may have implications for patients requiring long-term treatment for chronic glandular disorders. Neuromodulators are safe and effective for the noninvasive treatment of excess gland activity and can improve patients' quality of life. While substantial literature supports botulinum toxin treatments for hyperhidrosis, further studies are needed to characterize standard dosing and administration techniques for sialorrhea, bromhidrosis, and chromhidrosis.
Sections du résumé
BACKGROUND
BACKGROUND
Sialorrhea, hyperhidrosis, bromhidrosis, and chromhidrosis are common glandular disorders that substantially impact patients' health and quality of life. Botulinum toxin can safely and temporarily decrease gland secretions by targeting the parasympathetic cholinergic neurons, resulting in diminished saliva and sweat production.
OBJECTIVE
OBJECTIVE
The objective of this article is to describe the applications of neuromodulators for the treatment of salivary, eccrine, and apocrine glands.
METHODS
METHODS
PubMed was searched from inception to February 1, 2024 using search terms "neurotoxin," "botulinum toxin," "sialorrhea," "hyperhidrosis," "bromhidrosis," and "chromhidrosis."
RESULTS
RESULTS
Incobotulinumtoxin A and Rimabotulinumtoxin B are approved by the FDA for the treatment of sialorrhea. Onabotulinumtoxin A is the only FDA-approved botulinum toxin for axillary hyperhidrosis and is used off-label for hyperhidrosis of nonaxillary sites, bromhidrosis, and chromhidrosis. Compared to botulinum toxin serotype A, serotype B has been associated with more immunogenicity, which may have implications for patients requiring long-term treatment for chronic glandular disorders.
CONCLUSION
CONCLUSIONS
Neuromodulators are safe and effective for the noninvasive treatment of excess gland activity and can improve patients' quality of life. While substantial literature supports botulinum toxin treatments for hyperhidrosis, further studies are needed to characterize standard dosing and administration techniques for sialorrhea, bromhidrosis, and chromhidrosis.
Identifiants
pubmed: 39196843
doi: 10.1097/DSS.0000000000004262
pii: 00042728-202409001-00021
doi:
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
incobotulinumtoxinA
EC 3.4.24.69
rimabotulinumtoxinB
0Y70779M1F
Neurotransmitter Agents
0
onabotulinum toxin A
EC 3.4.24.69
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
S103-S111Informations de copyright
Copyright © 2024 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
Références
Parashar K, Adlam T, Potts G. The impact of hyperhidrosis on quality of life: a review of the literature. Am J Clin Dermatol 2023;24:187–98.
Scully C, Limeres J, Gleeson M, Tomás I, et al. Drooling. J Oral Pathol Med 2009;38:321–7.
Semkova K, Gergovska M, Kazandjieva J, Tsankov N. Hyperhidrosis, bromhidrosis, and chromhidrosis: fold (intertriginous) dermatoses. Clin Dermatol 2015;33:483–91.
Jost WH, Bäumer T, Laskawi R, Slawek J, et al. Therapy of sialorrhea with botulinum neurotoxin. Neurol Ther 2019;8:273–88.
Nawrocki S, Cha J. Botulinum toxin: pharmacology and injectable administration for the treatment of primary hyperhidrosis. J Am Acad Dermatol 2020;82:969–79.
Wu CJ, Chang CK, Wang CY, Liao YS, et al. Efficacy and safety of botulinum toxin A in axillary bromhidrosis and associated histological changes in sweat glands: a prospective randomized double-blind side-by-side comparison clinical study. Dermatol Surg 2019;45:1605–9.
Freeman MD, Margulies IG, Sanati-Mehrizy P, Burish N, et al. Nonaesthetic applications for botulinum toxin in plastic surgery. Plast Reconstr Surg 2020;146:157–70.
Isaacson SH, Ondo W, Jackson CE, Trosch RM, et al.; MYSTICOL Study Group. Safety and efficacy of RimabotulinumtoxinB for treatment of sialorrhea in adults: a randomized clinical trial. JAMA Neurol 2020;77:461–9.
Hockstein NG, Samadi DS, Gendron K, Handler SD. Sialorrhea: a management challenge. Am Fam Physician. 2004;69:2628–2634.
Jost WH, Steffen A, Berweck S. A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients. Expert Rev Neurother 2021;21:1059–68.
Jost WH, Friedman A, Michel O, Oehlwein C, et al. SIAXI: placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology 2019;92:e1982–e1991.
Berweck S, Bonikowski M, Kim H, Althaus M, et al. Placebo-controlled clinical trial of IncobotulinumtoxinA for sialorrhea in children: SIPEXI. Neurology 2021;97:e1425–e1436.
Tiigimäe-Saar J, Taba P, Tamme T. Does Botulinum neurotoxin type A treatment for sialorrhea change oral health? Clin Oral Investig 2017;21:795–800.
Ruiz-Roca JA, Pons-Fuster E, Lopez-Jornet P. Effectiveness of the botulinum toxin for treating sialorrhea in patients with Parkinson's disease: a systematic review. J Clin Med 2019;8:317.
Dashtipour K, Bhidayasiri R, Chen JJ, Jabbari B, et al. RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials. J Clin Mov Disord 2017;4:9.
Schnider P, Binder M, Kittler H, Birner P, et al. A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis. Br J Dermatol 1999;140:677–80.
Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ 2001;323:596–9.
Lowe NJ, Glaser DA, Eadie N, Daggett S, et al.; North American Botox in Primary Axillary Hyperhidrosis Clinical Study Group. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol 2007;56:604–11.
Solomon BA, Hayman R. Botulinum toxin type A therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol 2000;42:1026–9.
Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, et al. Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg 2002;28:822–7.
Baumann L, Slezinger A, Halem M, Vujevich J, et al. Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis. Dermatol Surg 2005;31:263–70.
Kinkelin I, Hund M, Naumann M, Hamm H. Effective treatment of frontal hyperhidrosis with botulinum toxin A. Br J Dermatol 2000;143:824–7.
George SM, Atkinson LR, Farrant PB, Shergill BS. Botulinum toxin for focal hyperhidrosis of the face. Br J Dermatol 2014;170:211–3.
Campanati A, Martina E, Gregoriou S, Kontochristopoulos G, et al. Botulinum toxin type A for treatment of forehead hyperhidrosis: multicenter clinical experience and review from literature. Toxins (Basel) 2022;14:372.
Campanati A, Giuliodori K, Martina E, Giuliano A, et al. Onabotulinumtoxin type A (Botox) versus Incobotulinumtoxin type A (Xeomin) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial. J Neural Transm (Vienna) 2014;121:21–6.
Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs Botox in primary palmar hyperhidrosis. Br J Dermatol 2003;149:1041–5.
Heckmann M, Teichmann B, Pause BM, Plewig G. Amelioration of body odor after intracutaneous axillary injection of botulinum toxin A. Arch Dermatol 2003;139:57–9.
Wang T, Dong J, He J. Long-term safety and efficacy of botulinum toxin A treatment in adolescent patients with axillary bromhidrosis. Aesthet Plast Surg 2018;42:560–4.
Wu JM, Mamelak AJ, Nussbaum R, McElgunn PS. Botulinum toxin a in the treatment of chromhidrosis. Dermatol Surg 2005;31:963–5.
Matarasso SL. Treatment of facial chromhidrosis with botulinum toxin type A. J Am Acad Dermatol 2005;52:89–91.
Beer K, Oakley H. Axillary chromhidrosis: report of a case, review of the literature and treatment considerations. J Cosmet Dermatol 2010;9:318–20.
Jost WH. The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson's disease. J Neural Transm (Vienna) 2016;123:51–5.
Dogu O, Apaydin D, Sevim S, Talas DU, et al. Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 2004;106:93–6.
So JI, Song DH, Park JH, Choi E, et al. Accuracy of ultrasound-guided and non-ultrasound-guided botulinum toxin injection into cadaver salivary glands. Ann Rehabil Med 2017;41:51–7.
Jongerius PH, Joosten F, Hoogen FJ, Gabreels FJ, et al. The treatment of drooling by ultrasound-guided intraglandular injections of botulinum toxin type A into the salivary glands. Laryngoscope 2003;113:107–11.
Sammons JE, Khachemoune A. Axillary hyperhidrosis: a focused review. J Dermatolog Treat 2017;28:582–90.
Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: therapeutic options. J Am Acad Dermatol 2019;81:669–80.
Ambache N. A further survey of the action of Clostridium botulinum toxin upon different types of autonomic nerve fibre. J Physiol 1951;113:1–17.
Lowe N, Naumann M, Eadie N. Treatment of hyperhidrosis with Botox (onabotulinumtoxinA): development, insights, and impact. Medicine (Baltimore) 2023;102:e32764.
Glaser DA, Loss R, Beddingfield F, Coleman W, et al. Four-year longitudinal data on the efficacy and safety of repeated botulinum toxin type A therapy for primary axillary hyperhidrosis [abstract]. J Am Acad Dermatol. 2007;56:AB61.
Castiglione L, Murariu M, Boeriu E, Enatescu I. Assessing botulinum toxin effectiveness and quality of life in axillary hyperhidrosis: a one-year prospective study. Diseases 2024;12:15.
Doft MA, Hardy KL, Ascherman JA. Treatment of hyperhidrosis with botulinum toxin. Aesthet Surg J 2012;32:238–44.
Glaser DA, Galperin TA. Botulinum toxin for hyperhidrosis of areas other than the axillae and palms/soles. Dermatol Clin 2014;32:517–25.
Matarasso SL. Ancillary techniques to relieve the pain associated with botulinum injections for palmar and plantar hyperhidrosis. Dermatol Surg 2022;48:699–700.
Malek-Khatabi A, Rad-Malekshahi M, Shafiei M, Sharifi F, et al. Botulinum toxin A dissolving microneedles for hyperhidrosis treatment: design, formulation and in vivo evaluation. Biomater Sci 2023;11:7784–804.
Watanabe H, Ohshima Y, Watanabe D. Therapeutic effectiveness of needle injection versus needle-free jet injector system for botulinum toxin type A in palmar hyperhidrosis. J Cutan Med Surg 2023;27:481–6.
Cohen PR. Genital rejuvenation: the next frontier in medical and cosmetic Dermatology. Dermatol Online J 2018;24:13030/qt27v774t5.